Mycobacterium Tuberculosis Market - Global Forecast 2026-2032

The Mycobacterium Tuberculosis market is evolving as health systems worldwide respond to shifting priorities, including faster diagnostics, resistance management, and the need for resilient operational models. Forward-looking decision-makers are reassessing strategies in light of operational gaps and trade complexities, creating new opportunities for differentiated solutions and integrated service delivery.

Market Snapshot: Mycobacterium Tuberculosis Landscape

The global Mycobacterium Tuberculosis market grew from USD 4.08 billion in 2025 to USD 4.33 billion in 2026. This sector is forecast to maintain a steady upward trajectory at a CAGR of 6.91%, reaching USD 6.52 billion by 2032. The market’s expansion is being driven by the widespread adoption of molecular diagnostics, growing pressure from drug resistance, and a shift toward decentralized and resilient healthcare delivery models.

Scope & Segmentation of the Mycobacterium Tuberculosis Market

The report covers the full spectrum of the Mycobacterium Tuberculosis value chain. Segmentation provides market clarity for stakeholders and guides commercialization strategy.

Product Types: Diagnostics, therapeutics, vaccines, and enabling technologies.
Diagnostics Modalities: Smear microscopy, culture-based methods, nucleic acid amplification technology, next-generation sequencing.
Application Areas: Drug-resistant TB, latent TB infection, active TB management.
End User Groups: Hospitals and clinics, diagnostic laboratories, public health agencies, research institutions.
Distribution Channels: Direct sales, distributors and tenders, digital procurement, e-commerce.
Regional Coverage: Americas; Europe, Middle East & Africa; Asia-Pacific.

Each segment faces unique operational realities, from resource-rich laboratories focused on advanced analytics to decentralized networks prioritizing accessibility, resilience, and quality of care.

Key Takeaways for Senior Decision-Makers

Market momentum reflects policy-driven adoption of molecular methods and integrated care pathways that reduce time-to-diagnosis and align treatment decisions with current resistance data.
Drug resistance is a leading pressure, spurring investment in rapid susceptibility testing and seamless diagnostic-therapeutic connections throughout TB management workflows.
Decentralization is creating demand for robust, user-friendly technologies and digital tools that extend quality and surveillance into community or peripheral settings.
Procurement criteria are expanding, prioritizing not only product effectiveness but also supply chain reliability, service support, and the ability to withstand shocks or disruptions.
Partnerships and regional collaborations are increasing in value, shaping both competitive strategy and the ability to serve diverse health system needs over the long term.
Stakeholder focus has shifted toward implementation support and integration, especially where programs rely on fragmented infrastructure or encounter variable regulatory expectations.

Tariff Impact: Navigating 2025 Supply and Pricing Friction

The introduction of United States tariffs in 2025 is altering the cost landscape for TB diagnostics and treatments, particularly for organizations relying on globally sourced components and US-linked contract manufacturing. These trade changes trigger additional supply-chain scrutiny, longer lead times, and possible adjustments in sourcing and contracting models—even in regions with limited US market exposure. Manufacturers and buyers that prioritize diversified sourcing, regional manufacturing footprints, and clarity in contract terms will reduce risk and preserve continuity in critical TB programs.

Methodology & Data Sources

This analysis integrates structured secondary research, including peer-reviewed literature, guidelines, and regulatory reviews, with validated insights from primary interviews. Stakeholder perspectives—ranging from laboratory leaders to program managers—were triangulated to map the interplay of workflows, adoption drivers, and operational realities with a focus on accuracy and regional nuance.

Why This Report Matters

Enables stakeholders to align innovation strategies with the real-world delivery challenges of Mycobacterium Tuberculosis care.
Provides actionable intelligence for procurement planning, mitigating trade and supply risks, and leveraging partnerships to reinforce program outcomes.
Supports tailored segmentation and commercialization efforts by illuminating distinct regional, technological, and application-specific drivers.

Conclusion

Organizations benefit most when they integrate credible technology with resilient operations and regional customization. Market participants who invest in supply chain robustness, connected service models, and partnership depth will be best positioned to drive enduring gains in TB control.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Mycobacterium Tuberculosis Market, by Drug Class

8.1. First Line Drugs
8.2. Second Line Drugs

9. Mycobacterium Tuberculosis Market, by Test Type

9.1. Culture Tests
9.2. Interferon Gamma Release Assays
9.3. Microscopy Tests
9.4. Molecular Tests
9.4.1. Lamp
9.4.2. Pcr
9.4.3. Xpert Mtb Rif
9.5. Skin Tests

10. Mycobacterium Tuberculosis Market, by Treatment Regimen

10.1. Drug Resistant Treatment
10.1.1. Extensively Drug Resistant
10.1.2. Multidrug Resistant
10.2. Drug Susceptible Treatment

11. Mycobacterium Tuberculosis Market, by End User

11.1. Clinics
11.2. Hospitals
11.3. Laboratories
11.4. Research Institutes

12. Mycobacterium Tuberculosis Market, by Distribution Channel

12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies

13. Mycobacterium Tuberculosis Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Mycobacterium Tuberculosis Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Mycobacterium Tuberculosis Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Mycobacterium Tuberculosis Market
17. China Mycobacterium Tuberculosis Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Molecular Inc.
18.6. Actiza Pharmaceutical Private Limited
18.7. Anuh Pharma Ltd.
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. Becton, Dickinson and Company
18.11. bioMérieux SA
18.12. Cadila Healthcare Ltd.
18.13. CapitalBio
18.14. Care Formulation Labs Private Limited
18.15. Cepheid, Inc.
18.16. Cipla Ltd.
18.17. DaAN Gene Company
18.18. Eiken Chemical Co., Ltd.
18.19. GlaxoSmithKline plc
18.20. Hain Lifescience GmbH
18.21. Hetero Labs Ltd.
18.22. Hologic, Inc.
18.23. Johnson & Johnson
18.24. Lupin Limited
18.25. Macleods Pharmaceuticals Ltd.
18.26. Merck & Co., Inc.
18.27. Molbio Diagnostics Private Limited
18.28. Novartis AG
18.29. Otsuka Pharmaceutical Co., Ltd.
18.30. Pfizer Inc.
18.31. QIAGEN N.V.
18.32. Roche Diagnostics International AG
18.33. Sandoz International GmbH
18.34. Sanofi S.A.
18.35. Serum Institute of India Pvt. Ltd.
18.36. Thermo Fisher Scientific Inc.
18.37. Titan Biotech Limited
18.38. Viatris Inc.

List of Figures

FIGURE 1. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY FIRST LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SECOND LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MICROSCOPY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LAMP, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY XPERT MTB RIF, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SKIN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY EXTENSIVELY DRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MULTIDRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG SUSCEPTIBLE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 109. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 110. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 111. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. EUROPE MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 124. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 125. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 126. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 127. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AFRICA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 141. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 142. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 143. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 144. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. ASEAN MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 149. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 150. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 151. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 152. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. GCC MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 165. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 166. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 167. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 168. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. BRICS MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 173. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 174. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 175. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 176. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. G7 MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 180. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 181. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 182. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 183. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 184. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. NATO MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 198. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 199. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 200. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DRUG RESISTANT TREATMENT, 2018-2032 (USD MILLION)
TABLE 201. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. CHINA MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Mycobacterium Tuberculosis market report include:

Abbott Molecular Inc.
Actiza Pharmaceutical Private Limited
Anuh Pharma Ltd.
AstraZeneca PLC
Bayer AG
Becton, Dickinson and Company
bioMérieux SA
Cadila Healthcare Ltd.
CapitalBio
Care Formulation Labs Private Limited
Cepheid, Inc.
Cipla Ltd.
DaAN Gene Company
Eiken Chemical Co., Ltd.
GlaxoSmithKline plc
Hain Lifescience GmbH
Hetero Labs Ltd.
Hologic, Inc.
Johnson & Johnson
Lupin Limited
Macleods Pharmaceuticals Ltd.
Merck & Co., Inc.
Molbio Diagnostics Private Limited
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
QIAGEN N.V.
Roche Diagnostics International AG
Sandoz International GmbH
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Thermo Fisher Scientific Inc.
Titan Biotech Limited
Viatris Inc.

Table Information

Report Attribute	Details
No. of Pages	191
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 4.33 Billion
Forecasted Market Value ( USD ) by 2032	$ 6.52 Billion
Compound Annual Growth Rate	6.9%
Regions Covered	Global
No. of Companies Mentioned	35

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3513EUR$3,939USD£3,047GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3789EUR$4,249USD£3,286GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5136EUR$5,759USD£4,454GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6215EUR$6,969USD£5,390GBP

Market Snapshot: Mycobacterium Tuberculosis Landscape

Scope & Segmentation of the Mycobacterium Tuberculosis Market

Key Takeaways for Senior Decision-Makers

Tariff Impact: Navigating 2025 Supply and Pricing Friction

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Mycobacterium Tuberculosis Test Kit Market - Global Forecast 2025-2030

Mycobacterium Tuberculosis Nucleic Acid Detection Kit Market - Global Forecast to 2030

Mycobacterium Tuberculosis PCR Detection Kit Market Report: Trends, Forecast and Competitive Analysis to 2031

Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Tuberculosis Diagnostics Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034